Latest news with #44Countries
Forbes
09-07-2025
- Forbes
World's 200 Most Dangerous Passwords Revealed — Change Yours If Listed
Is your password on the world's most used list? Passwords can't live without them, oh, hold on, actually you can. Passkeys are way more secure, and increasingly, platforms, products, and services are making them available to users. That's the good news. The bad news is that, for hundreds of millions of users supposedly securing billions of accounts, weak and easily compromised passwords remain the reality. With lists of such compromised passwords readily available on the criminal underground and even the surface web, using one of the 200 most commonly used, and therefore most dangerous, passwords is tantamount to handing the keys of your account to hackers. If your passwords are on this list, they most certainly are getting in. 2.5TB Credentials From 44 Countries Database Analyzed — 200 Most Dangerous Passwords Revealed There is no shortage of compromised and leaked password lists floating around the web, dark or surface, if you care to go and look. And, believe me, threat actors know exactly where to find the most valuable of them, available in credential-stuffing, password spraying, format for a small fee. That, dear reader, is the sorry state of login security today. It's why the likes of Google are urging users to replace passwords with passkeys. If you can't, and you are stuck with using passwords, then, please, at least make them long, strong and secure. Use a password manager to create random password strings that are too complex for you to remember, because you won't have to remember them. Use passphrases; use anything other than the 200 dangerous passwords on this list. Compiled jointly by NordPass and NordStellar, the 200 most used and dangerous passwords to use list emerged from an analysis of a 2.5TB database of passwords found on the dark and surface webs, across 44 countries in total, and stolen by malware or exposed in data leaks. 'We focused only on the statistical information,' the researchers said, 'so no personal data from internet users was included in this research.' Let's tease the results out a little by starting with the 10 most dangerous passwords that were attributed to U.S. users: Interestingly, this features nine of the ten most used passwords globally, but in a different order. The only unique password, as far as the U.S. is concerned, was the (not so) highly original password1. A rubbish password that featured at number 17 in the global list. OK, so let's move on to the global list, of which I'll just focus on the first 50 — please use the already provided link to access the full database of 200. Needless to say, if any of your passwords appear here, or in the full list, then change them as a matter of some urgency, and while doing so, give your neck a wobble for using them in the first place. What were you thinking?
Medscape
26-06-2025
- Health
- Medscape
Nerandomilast May Slow Down Progressive Pulmonary Fibrosis
TOPLINE: In a phase 3 study, nerandomilast administered at 18 mg or 9 mg twice daily slowed the progression of pulmonary fibrosis in adults with progressive pulmonary fibrosis. METHODOLOGY: In a previous study, nerandomilast, a preferential inhibitor of phosphodiesterase 4B, was found to slow the progression of idiopathic pulmonary fibrosis. The present phase 3, randomized trial conducted at multiple sites across 44 countries investigated the efficacy and safety of nerandomilast in patients with a confirmed diagnosis of interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis. The study enrolled 1176 patients (mean age, 66.4 years; mean forced vital capacity [FVC], 70.1% of the predicted value) who were randomly assigned to receive either 18 mg or 9 mg nerandomilast or placebo twice daily. Patients were stratified on the basis of background nintedanib therapy and fibrotic patterns observed on high-resolution CT. The mean exposure duration was approximately 14.5 months in each group. The primary endpoint was the absolute change from baseline in FVC at week 52, and key secondary endpoints were time to first acute exacerbation of ILD, respiratory-related hospitalization, or death. TAKEAWAY: Nerandomilast significantly reduced the decline in FVC compared with placebo, with adjusted differences of 67.2 mL for the 18 mg dose and 81.1 mL for the 9 mg dose (P < .001 for both). This reduction in lung function decline was sustained regardless of background therapy. The study could not confirm the less frequent occurrence of a first acute exacerbation of ILD, respiratory-related hospitalization, or death in the nerandomilast groups compared with the placebo group. Deaths occurred in a lower proportion of patients receiving nerandomilast at 18 mg (hazard ratio [HR], 0.48; 95% CI, 0.30-0.79), and 9 mg (HR, 0.60; 95% CI, 0.38-0.95) doses than in those receiving placebo. Diarrhea was the most frequently occurring adverse event, reported in 36.6%, 29.5%, and 24.7% patients in the 18 mg nerandomilast, 9 mg nerandomilast, and placebo groups, respectively. Adverse events leading to regimen interruption or permanent discontinuation occurred at similar rates across the groups. IN PRACTICE: 'The FIBRONEER-ILD trial showed that nerandomilast at a dose of 18 mg twice daily or 9 mg twice daily slowed the progression of pulmonary fibrosis in patients with progressive pulmonary fibrosis,' the authors wrote. 'The current clinical trials represent a meaningful advancement in the treatment landscape for persons living with IPF [idiopathic pulmonary fibrosis] and progressive ILD other than IPF,' the author of an associated editorial wrote. SOURCE: This study was led by Toby M. Maher, MD, Department of Pulmonary, Critical Care, and Sleep Medicine, Keck School of Medicine, University of Southern California, Los Angeles. It was published online on May 19, 2025, in The New England Journal of Medicine. LIMITATIONS: The trial was not powered to evaluate nerandomilast in specific subgroups, including patients grouped by ILD diagnosis. Additionally, patients taking certain medications, particularly mycophenolate, that are commonly used in treating autoimmune diseases were excluded from the trial. DISCLOSURES: This study was funded by Boehringer Ingelheim. Nine authors declared being employees of Boehringer Ingelheim, while few declared serving as consultants. Some other authors reported having other financial ties with various pharmaceutical companies. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
